natgillin/translations-raw huggingface dataset:
The vaccine has not been tested in breeding bulls and should therefore not be used in breeding bulls. 
Cepiva niso preskusili pri bikih v času parjenja.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT 
NAVODILO ZA UPORABO Bovela liofilizat in vehikel za suspenzijo za injiciranje za govedo IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
Keep the vials in the outer carton. 
Viale shranjujte v zunanji ovojnini.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
Keep the lyophilisate and the solvent vials in the outer carton. 
Shranjujte viali z liofilizatom in vehiklom v zunanji ovojnini.
Furthermore, a increase of the rectal body temperature was common within 4 hours following administration and spontaneously resolves within 24 hours (see section “Adverse reactions”). 
Nadalje je bil znotraj 4 ur po cepljenju pogost porast rektalne telesne temperature, ki v 24 urah spontano izzveni (glejte poglavje “Neželeni učinki”).
Lyophilisate: Off-white colour without foreign matter. 
Liofilizat: sivo bele barve brez tujih snovi Vehikel: bistra, brezbarvna raztopina
Solvent for Bovela 
Vehikel za cepivo Bovela
EU/2/14/176/001 5 doses and 10 ml EU/2/14/176/002 5 doses and 10 ml (4 x) EU/2/14/176/003 5 doses and 10 ml (6 x) EU/2/14/176/004 5 doses and 10 ml (10 x) 
EU/2/14/176/002 5 odmerkov in 10 ml (4 x) EU/2/14/176/003 5 odmerkov in 10 ml (6 x)
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box: 5 doses, 10 doses, 25 doses, 50 doses lyophilisate and 10 ml, 20 ml, 50 ml, 100 ml solvent 
Kartonska škatla: 5 odmerkov, 10 odmerkov, 25 odmerkov, 50 odmerkov liofilizata in 10 ml, 20 ml, 50 ml, 100 ml vehikla
EXP {month/year} Once reconstituted use within: 8 hours. 
Rok uporabnosti rekonstituiranega zdravila: 8 ur.
Shelf life after reconstitution: 8 hours. 
Rok uporabnosti zdravila po rekonstituciji v skladu z navodili: 8 ur.
Therefore, use during pregnancy should only be on a case-by-case basis decided by the responsible veterinarian, taking into consideration e.g. the BVD immunological status of the animal, the time-span between vaccination and mating/insemination, the stage of pregnancy and the risk of infection. 
imunološko stanje živali, kar se tiče BVD, časovni razmik med cepljenjem in parjenjem/oploditvijo,
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate vials: 5 doses, 10 doses and 25 doses 
Viale z liofilizatom: 5 odmerkov, 10 odmerkov in 25 odmerkov
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVAJALEC BIOLOŠKIH UČINKOVIN IN PROIZVAJALEC,
Bovela lyophilisate and solvent for suspension for injection for cattle 
Bovela liofilizat in vehikel za suspenzijo za injiciranje za govedo
Keep the bottle in the outer carton. 
Plastenko shranjujte v zunanji ovojnini.
Mild swellings or nodules up to 3 cm diameter were observed at the injection site after administration of a 10-fold overdose and disappeared within 4 days post vaccination. 
3 cm v premeru, ki so izginili v 4 dneh po cepljenju.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Solvent bottles: 10 ml, 20 ml, 50 ml, 100 ml 
Plastenke z vehiklom: 10 ml, 20 ml, 50 ml, 100 ml
Marketing authorisation holder and manufacturer responsible for batch release: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein 
Imetnik dovoljenja za promet z zdravilom in proizvajalec, odgovoren za sproščanje serij: Boehringer Ingelheim Vetmedica GmbH
1 lyophilisate vial of 10 ml (5 doses), 20 ml (10 doses), 50 ml (25 doses) or 100 ml (50 doses) and 1 solvent bottle of 10 ml, 20 ml, 50 ml or 100 ml packed in one cardboard box. 
1 viala, ki vsebuje 10 ml (5 odmerkov), 20 ml (10 odmerkov), 50 ml (25 odmerkov) ali 100 ml (50 odmerkov) liofilizata in 1 plastenka, ki vsebuje 10 ml, 20 ml, 50 ml ali 100 ml vehikla, pakirani v eni kartonasti škatli.
6 lyophilisate vials of 10 ml (5 doses), 20 ml (10 doses), 50 ml (25 doses) or 100 ml (50 doses) and 6 solvent bottles of 10 ml, 20 ml, 50 ml or 100 ml packed in one cardboard box. 
6 vial, ki vsebujejo 10 ml (5 odmerkov), 20 ml (10 odmerkov), 50 ml (25 odmerkov) ali 100 ml (50 odmerkov) liofilizata in 6 plastenk, ki vsebujejo 10 ml, 20 ml, 50 ml ali 100 ml vehikla, pakiranih v eni kartonasti škatli.
4 lyophilisate vials of 10 ml (5 doses), 20 ml (10 doses), 50 ml (25 doses) or 100 ml (50 doses) and 4 solvent bottles of 10 ml, 20 ml, 50 ml or 100 ml packed in one cardboard box. 
4 viale, ki vsebujejo 10 ml (5 odmerkov), 20 ml (10 odmerkov), 50 ml (25 odmerkov) ali 100 ml (50 odmerkov) liofilizata in 4 plastenke, ki vsebujejo 10 ml, 20 ml, 50 ml ali 100 ml vehikla, pakirane v eni kartonasti škatli.
10 lyophilisate vials of 10 ml (5 doses), 20 ml (10 doses), 50 ml (25 doses) or 100 ml (50 doses) and 10 solvent bottles of 10 ml, 20 ml, 50 ml or 100 ml packed in one cardboard box. 
10 vial, ki vsebujejo 10 ml (5 odmerkov), 20 ml (10 odmerkov), 50 ml (25 odmerkov) ali 100 ml (50 odmerkov) liofilizata in 10 plastenk, ki vsebujejo 10 ml, 20 ml, 50 ml ali 100 ml vehikla, pakiranih v eni kartonasti škatli.
Shelf life of the solvent: 
Vehikel: Rok uporabnosti vehikla:
EU number 
Eu številka
Content (concentration) Package size 
Vsebnost (koncentracija) Velikost pakiranja
Further information on Striascan can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/striascan. 
Nadaljnje informacije o zdravilu Striascan so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/striascan.
• dementia (loss of intellectual function). 
• demence (poslabšanja kognitivnih sposobnosti).
A scan is taken 3 to 6 hours after the injection. 
Slikanje se opravi od tri do šest ur po injiciranju.
Why is Striascan authorised in the EU? 
Zakaj je bilo zdravilo Striascan odobreno v EU?
The European Medicines Agency concluded that, in accordance with EU requirements, Striascan has been shown to be comparable to DaTSCAN. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Striascan primerljivo z zdravilom DaTSCAN.
Striascan is a diagnostic medicine. 
Striascan je diagnostično zdravilo.
What measures are being taken to ensure the safe and effective use of Striascan? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Striascan?
An overview of Striascan and why it is authorised in the EU 
Pregled zdravila Striascan in zakaj je odobreno v EU
The medicine is used to help in the diagnosis of the following conditions in adults (aged 18 years or over): 
Zdravilo se uporablja pri odraslih (starih 18 let ali več) kot pomoč pri diagnosticiranju naslednjih bolezni:
Because Striascan is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Striascan generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
As for every medicine, the company provided studies on the quality of Striascan. 
Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Striascan.
Because tremor can also occur in ‘essential tremor' (tremor whose cause is unknown), Striascan can help distinguish between essential tremor and diseases related to Parkinson's disease; 
Ker lahko tremor nastopi tudi v obliki „esencialnega tremorja“ (tremorja, katerega vzrok je neznan), lahko zdravilo Striascan pripomore k razločevanju esencialnega tremorja od obolenj, povezanih s Parkinsonovo boleznijo;
Side effects reported with Striascan are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Striascan, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Striascan have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Striascan upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Other information about Striascan 
Druge informacije o zdravilu Striascan
What are the benefits and risks of Striascan? 
Kakšne so koristi in tveganja, povezani z zdravilom Striascan?
If this happens, the amount of Striascan attaching to these nerve cells is greatly reduced, which can be seen on the scan. 
Če se to zgodi, je količina zdravila Striascan, ki se veže na te živčne celice, precej manjša, kar je razvidno s slik.
As for all medicines, data on the use of Striascan are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Striascan stalno spremljajo.
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, DaTSCAN, and do not need to be repeated for Striascan. 
Študije o koristih in tveganjih učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom DaTSCAN, zato jih ni treba ponoviti za zdravilo Striascan.
Between 1 to 4 hours before receiving Striascan, patients must also take another medicine, such as iodine tablets, to prevent the radioactive iodine in Striascan from getting into the thyroid gland. 
Od ene do štiri ure pred injiciranjem zdravila Striascan morajo bolniki prejeti drugo zdravilo, kot so na primer jodove tablete, da se prepreči privzem radioaktivnega joda iz zdravila Striascan v ščitnici.
For more information about using Striascan, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Striascan glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Striascan is given by slow injection lasting at least 15 to 20 seconds into an arm vein. 
Zdravilo Striascan se daje v veno na roki s počasnim injiciranjem, ki traja najmanj 15 do 20 sekund.
In patients with Parkinson's disease and related diseases, and in patients with dementia with Lewy bodies, there is typically a loss of the dopamine-containing nerve cells in the striatum. 
Pri bolnikih s Parkinsonovo boleznijo in drugimi sorodnimi boleznimi ter pri bolnikih z demenco z Lewyjevimi telesci navadno pride do odmiranja živčnih celic, ki vsebujejo dopamin, v striatumu.
Striascan is used to help distinguish between a type of dementia known as ‘dementia with Lewy bodies' and Alzheimer's disease. 
Zdravilo Striascan se uporablja kot pomoč pri razlikovanju vrste demence, poznane kot demenca z Lewyjevimi telesci, od Alzheimerjeve bolezni.
Resuscitation equipment should be available before Striascan is given, in case the patient has an allergic reaction. 
Ob dajanju zdravila Striascan mora biti na voljo oprema za oživljanje za primer, kadar pri bolniku pride do alergijske reakcije.
• movement disorders such as those in Parkinson's disease and other related diseases, where a loss of nerve cells leads to tremor (shaking), gait disturbance (problems with the way the patient walks) and stiffness of the muscles. 
• motenj gibanja, kot so tiste, ki se pojavijo pri Parkinsonovi bolezni in drugih sorodnih boleznih, pri katerih odmiranje živčnih celic povzroči tremor (tresavico), motnje pri hoji in otrdelost mišic.
There was no need for ‘bioequivalence' studies to investigate whether Striascan is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. 
Izvedba študije „bioekvivalence“, s katero bi raziskali, ali se zdravilo Striascan absorbira podobno kot referenčno zdravilo in tako doseže enako raven učinkovine v krvi, ni bila potrebna.
It is used to detect the loss of nerve cells in an area of the brain called the striatum, specifically the cells that release dopamine, a chemical messenger. 
Uporablja se za zaznavanje odmiranja živčnih celic na območju možganov, ki se imenuje striatum, zlasti celic, ki sproščajo kemični prenašalec dopamin.
Striascan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called DaTSCAN. 
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje DaTSCAN.
What is Striascan and what is it used for? 
Kaj je zdravilo Striascan in za kaj se uporablja?
This build-up can be seen using an imaging technique called single-photon-emission computed tomography (SPECT), which detects the radioactive iodine-123. 
Kopičenje te snovi se lahko zazna s tehniko slikanja, imenovano računalniško podprta scintigrafska tomografija s sevalci gama (single-photon-emission computed tomography - SPECT), ki zaznava radioaktivni jod-123.
Ioflupane attaches specifically to structures on nerve cell endings that are responsible for the transport of dopamine. 
Joflupan se veže na strukture na živčnih končičih, ki so odgovorne za prenos dopamina.
Striascan is only handled and given by people who have experience in the safe handling of radioactive materials. 
Z zdravilom Striascan lahko rokujejo in ga dajejo samo osebe, ki imajo izkušnje z uporabo radioaktivnih snovi.
It contains a substance called ioflupane, which is labelled with 123I (iodine-123), a radioactive form of iodine. 
Vsebuje učinkovino, imenovano joflupan, ki je radiooznačena z jodom-123 (123I), tj. radioaktivno obliko joda.
This enables diseases related to Parkinson's disease to be distinguished from essential tremor, and for Lewy body dementia to be distinguished from Alzheimer's disease. 
To omogoča razločevanje bolezni, povezanih s Parkinsonovo boleznijo, od esencialnega tremorja ter demence z Lewyjevimi telesci od Alzheimerjeve bolezni.
This is because Striascan is given by injection into a vein, so the active substance is delivered straight into the bloodstream. 
Razlog za to je dejstvo, da se zdravilo Striascan daje z injiciranjem v veno, zaradi česar učinkovina vstopi neposredno v krvni obtok.
Striascan can only be obtained with a prescription and should only be used in patients who have been referred by a doctor with experience in the management of movement disorders or dementia. 
Predpisovanje in izdaja zdravila Striascan je le na recept, uporabljati pa se sme samo pri bolnikih, ki jih na pregled napotijo zdravniki, izkušeni na področju zdravljenja motenj gibanja ali demence.
Therefore, the Agency's view was that, as for DaTSCAN, the benefit of Striascan outweighs the identified risk and it can be authorised for use in the EU. 
Zato je menila, da koristi zdravila Striascan enako kot pri zdravilu DaTSCAN odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
How has Striascan been studied? 
Kako je bilo zdravilo Striascan raziskano?
How is Striascan used? 
Kako se zdravilo Striascan uporablja?
Striascan (ioflupane ( 
Striascan (joflupan (123I))
I) is distributed by the blood and builds up in the striatum, where it attaches to the structures that transport dopamine. 
Po injiciranju zdravila Striascan joflupan (123I) po krvi potuje do striatuma, kjer se nakopiči in veže na strukture za prenos dopamina.
How does Striascan work? 
Kako zdravilo Striascan deluje?
It contains five live rotavirus strains, each carrying a different antigen (G1, G2, G3, G4 and P1[8]). 
Vsebuje pet živih sevov rotavirusov, od katerih ima vsak drugačen antigen (G1, G2, G3, G4 in P1[8]).
The European Commission granted a marketing authorisation valid throughout the European Union for RotaTeq on 27 June 2006. 
Evropska komisija je dovoljenje za promet z zdravilom RotaTeq, veljavno po vsej Evropski uniji, izdala dne 27. junija 2006.
It is available as a solution in a single-dose tube. 
Na voljo je kot raztopina v enoodmerni tubi.
There are various types of rotaviruses that cause gastroenteritis. 
Obstajajo različni tipi rotavirusov, ki povzročajo gastroenteritis.
The full EPAR for RotaTeq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo RotaTeq je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It must also not be used in babies whose immune system is weakened. 
Prav tako ga ne smejo prejeti otroci z oslabljenim imunskim sistemom.
It is recommended that the last dose be given to the child by the age of 20 to 22 weeks. 
Priporočljivo je, da zadnji odmerek cepiva otrok dobi do dopolnjenega 20. do 22. tedna starosti.
The contents of the tube of RotaTeq are given directly into the baby's mouth. 
Vsebino tube zdravila RotaTeq je treba dati neposredno v usta dojenčka.
What measures are being taken to ensure the safe and effective use of RotaTeq? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila RotaTeq?
The CHMP decided that RotaTeq's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila RotaTeq večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
This document is a summary of the European public assessment report (EPAR) for RotaTeq. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo RotaTeq.
For more information about treatment with RotaTeq, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom RotaTeq preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Other information about RotaTeq: 
Druge informacije o zdravilu RotaTeq:
If necessary it may be given up to the age of 32 weeks. 
Po potrebi se cepivo lahko da vse do 32. tedna starosti.
RotaTeq should never be injected under any circumstances. 
Cepiva RotaTeq se v nobenem primeru ne sme injicirati.
When a baby is given the vaccine, the immune system (the system that fights diseases) makes antibodies against these antigens, which help prevent infections caused by rotaviruses that occur naturally and carry the same or very similar antigens. 
Ko otrok prejme cepivo, imunski sistem (obrambni sistem proti boleznim) izdela protitelesa proti tem antigenom, s čimer pripomore k preprečevanju okužb, ki jih povzročajo naravno prisotni rotavirusi z enakimi ali zelo podobnimi antigeni.
The number of cases of rotavirus gastroenteritis due to viruses with the same antigens as in the vaccine decreased following vaccination with RotaTeq. 
Število primerov rotavirusnega gastroenteritisa zaradi virusov z enakim antigenom, kot je v cepivu, se je po cepljenju s cepivom RotaTeq zmanjšalo.
The first dose should be given six weeks after birth at the earliest. 
Prvi odmerek morajo prejeti najmanj šest tednov po rojstvu.
RotaTeq rotavirus vaccine, live 
RotaTeq cepivo proti rotavirusu, živo
RotaTeq contains viruses that carry the antigens for some of the most commonly occurring types of rotaviruses. 
Cepivo RotaTeq vsebuje viruse, ki nosijo antigene za nekaj najpogostejših tipov rotavirusov.
The first dose is given when the baby is between 6 and 12 weeks of age. 
S prvim odmerkom je treba dojenčka cepiti pri starosti med 6 in 12 tednov.
About half of the babies received RotaTeq, and the others received placebo (a dummy vaccine). 
Približno polovica dojenčkov je prejemala cepivo RotaTeq, drugi pa so prejemali placebo (cepivo brez zdravilne učinkovine).
RotaTeq is used in babies from 6 to 32 weeks of age to protect against gastroenteritis (diarrhoea and vomiting) caused by rotavirus infections. 
Zdravilo RotaTeq se uporablja pri dojenčkih, starih od 6 do 32 tednov, za preprečevanje gastroenteritisa (driske in bruhanja), ki ga povzroča okužba z rotavirusi.
A risk management plan has been developed to ensure that RotaTeq is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila RotaTeq je bil pripravljen načrt obvladovanja tveganj.
Overall, the studies of RotaTeq involved over 72,000 babies, including about 2,000 premature babies. 
V študije cepiva RotaTeq je bilo vključenih skupno 72 000 dojenčkov, med katerimi je bilo približno 2 000 nedonošenčkov.
The main measure of effectiveness, which was studied in 6,000 babies, was the number of babies who developed rotavirus gastroenteritis during the following rotavirus season (the time of the year when rotaviruses are known to circulate and cause infection, generally during the cooler months in winter to early spring). 
Glavno merilo učinkovitosti, ki so ga proučevali pri 6 000 dojenčkih, je bilo število otrok, pri katerih se je v naslednji rotavirusni sezoni (obdobju v letu, ko se pričakuje širjenje rotavirusov in pojav okužb, po navadi v hladnejših mesecih - od zime do zgodnje pomladi) pojavil rotavirusni gastroenteritis.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for RotaTeq, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
RotaTeq is given according to official recommendations. 
Cepivo RotaTeq se daje v skladu z uradnimi priporočili.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for RotaTeq. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has RotaTeq shown during the studies? 
Kakšne koristi je zdravilo RotaTeq izkazalo med študijami?
Among the almost 6,000 babies in whom the main measure of effectiveness was studied, 82 of the babies vaccinated with RotaTeq developed rotavirus gastroenteritis (one with severe gastroenteritis) compared with 315 of the babies who received placebo (51 severe cases). 
Od skoraj 6 000 dojenčkov, pri katerih so proučevali glavno merilo učinkovitosti cepiva, se je rotavirusni gastroenteritis pojavil pri 82 dojenčkih, cepljenih s cepivom RotaTeq (pri enem hud gastroenteritis), v primerjavi s 315 dojenčki, ki so prejemali placebo (51 hudih primerov).
RotaTeq can be given at the same time as other vaccinations (except the oral polio vaccine, when a two-week interval is needed between the two vaccines). 
Cepivo RotaTeq se lahko daje sočasno z drugimi cepivi (izjema je peroralno cepivo proti otroški ohromelosti (polio), v tem primeru je časovni razmik med cepljenji s tema cepivoma dva tedna).
RotaTeq must not be used in babies who are hypersensitive (allergic) to the active substance or any of the other ingredients, or who showed signs of allergy after receiving a dose of RotaTeq or another vaccine against rotavirus in the past. 
Zdravilo RotaTeq se ne sme uporabiti pri dojenčkih, ki so preobčutljivi za (alergični na) zdravilno učinkovino ali katero koli drugo sestavino zdravila, ali dojenčkih, ki so v preteklosti kazali znake alergije po prejemu odmerka cepiva RotaTeq ali drugega cepiva proti rotavirusom.
The most common side effects with RotaTeq (seen in more than 1 patient in 10) are pyrexia (fever), diarrhoea and vomiting. 
Najpogostejši neželeni učinki cepiva RotaTeq (opaženi pri več kot 1 bolniku od 10) so bili pireksija (povišana telesna temperatura), driska in bruhanje.
RotaTeq is given as three doses, with at least four weeks between each dose. 
Zdravilo RotaTeq se daje v treh odmerkih, pri čemer mora biti razmik med posameznima odmerkoma vsaj štiri tedne.
For the full list of all side effects reported with RotaTeq, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila RotaTeq, glejte navodilo za uporabo.